|
|
ASMC'11 St. Petersburg |
| Confirmed Speakers |
| | Metal-Catalyzed C–H Bond Functionalizations for Sustainable Synthesis |
Prof. Lutz ACKERMANN
(GEORG-AUGUST UNIVERSITY GOETTINGEN, Goettingen, Germany) |
|
| | Chemical Probes for Epigenetics |
Dr Mark BUNNAGE
(PFIZER, Boston, United States) |
|
| | Novel Metabotropic Glutamate Receptor 4 (mGluR4) Allosteric Potentiators for the Treatment of Parkinsons’s Disease |
Dr Sylvain CELANIRE
(ADDEX PHARMACEUTICALS, Geneva, Switzerland) |
|
| | A few of my Favorite Rings: Catalysis Inspired by Lactones and Lactams |
Prof. Vy M. DONG
(UNIVERSITY OF TORONTO, Toronto, Canada) |
|
| | Tofacitinib (CP-690,550): Discovery of a Potent and Selective JAK Inhibitor |
Dr Mark FLANAGAN
(PFIZER, Connecticut, United States) |
|
| | Antibody Directed Cytotoxics |
Prof. John FLYGARE
(GENENTECH, California, United States) |
|
| | From Homer to Hedgehog: Chemistry, Biological Investigations and Medical Perspectives of Cyclopamine |
Prof. Athanassios GIANNIS
(UNIVERSITY OF LEIPZIG, Leipzig, Germany) |
|
| | Bicyclic Peptides with Tailored Binding Specificities for Therapeutic Application |
Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland) |
|
| | Regioselective Reactions on a Chiral Substrate Controlled by the Configuration of a Chiral Catalyst |
Prof. Henri KAGAN
(UNIVERSITY PARIS-SUD 11, ORSAY Cedex, France) |
|
| | Discovery and Development of Novel Antimalarials |
Dr Rodney KIP GUY
(ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States) |
|
| | Target Synthesis Directed Methodology Development |
Prof. Dawei MA
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China) |
|
| | Minor Enantiomer Recycling –
A Strategy for Improving Enantioselectivity
|
Prof. Christina MOBERG
(KTH SCHOOL OF CHEMICAL SCIENCE AND ENGINEERING, Stockholm, Sweden) |
|
| | Magical Power of d-Block Transition Metals—Pd-Catalyzed Cross-Coupling and Zr-Catalyzed Asymmetric carboalumination of Alkenes (ZACA) |
Prof. Ei-ichi NEGISHI
(PURDUE UNIVERSITY, West Lafayette, United States) |
|
| | Maitotoxin. An Inspiration for Synthesis |
Prof. K.C. NICOLAOU
(THE SCRIPPS RESEARCH INSTITUTE & UNIVERSITY OF CALIFORNIA, Houston, United States) |
|
| | Small Molecules Inhibitors of the WNT Signalling Pathway with Potential Applications in Oncology |
Dr Alessandro PADOVA
(SIENA BIOTECH, Siena, Italy) |
|
| | Design Strategy for Preparation of Drug-like Polyheterocycles with Privileged Substructures for Discovery of Specific Small Molecule Modulators |
Prof. Seung Bum PARK
(SEOUL NATIONAL UNIVERSITY, Seoul, Korea, South) |
|
| | Synthesis of Marine Polyketides as Promising Anticancer Agents |
Prof. Ian PATERSON
(CAMBRIDGE UNIVERSITY, Cambridge, United Kingdom) |
|
| | GPR119: Knowledge Based Lead Identification |
Dr Sherrie L. PIETRANICO-COLE
(ROCHE, NUTLEY NJ, United States) |
|
| | A Step Closer to Hepatitis C Remedy: TMC435, an HCV Protease Inhibitor in Advanced Clinical Trial |
Dr Pierre RABOISSON
(JANSSEN PHARMACEUTICAL COMPANIES, Beerse, Belgium) |
|
| | The Many Uses of Noncovalent Mass Spectrometry in Early-stage Drug Discovery |
Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France) |
|
| | The Resurgence of Covalent Drugs |
Dr Juswinder SINGH
(AVILA THERAPEUTICS, United States) |
|
| | Lessons in Chemoselectivity: Total Synthesis of Polyphenolic Natural Products |
Prof. Scott SNYDER
(COLUMBIA UNIVERSITY, New York, United States) |
|
| | Asymmetric Synthesis of Bioactive Molecules |
Prof. Mikiko SODEOKA
(RIKEN, Hirosawa, Japan) |
|
| | Biochemical Efficiency, a Metrics for an Optimal Molecular Mechanism of Action |
Dr David SWINNEY
(IRND3, Mountain View, United States) |
|
| | Drug Discovery by Programmed Self-Assembly |
Prof. Nicolas WINSSINGER
(UNIVERSITY OF STRASBOURG, Geneva, Switzerland) |
|
| | Bromodomains a New Class of Epigenetic Targets Ripe for Small Molecule Drug Discovery |
Dr Jason WITHERINGTON
(GLAXOSMITHKLINE R&D, Stevenage, United Kingdom) |
|
| | Validation of N-Myristoyltransferase as a Drug Target |
Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom) |
|
| | Accelerated C-H Activation Reactions: Enantioselectivity and Positional Selectivity |
Prof Jin-Quan YU
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States) |
|
| Selected Oral Communications |
| | Small Molecule Inhibitors of the Neuropilin-1 VEGF-A Interaction |
Dr Philip FALLON
(DOMAINEX, Saffron Walden, United Kingdom) |
|
| | Halogen Bonding in Protein–ligand Interactions |
Mr Leo HARDEGGER
(ETH ZURICH, Zürich, Switzerland) |
|
| | The Chemical Biology Consortium-
and Experimental Therapeutics Program |
Dr Sanjay MALHOTRA
(NATIONAL CANCER INSTITUTE, Frederick, United States) |
|
| | Adventures in Medicinal Chemistry and Knowledge Capture |
Dr Alexander MAYWEG
(F. HOFFMANN-LA ROCHE LTD, BASEL, Switzerland) |
|
| | Identification of Bisaryloxy Azetidine Urea Derivatives as Fatty Acid Amide Hydrolase Inhibitors |
Dr Hans MEISSNER
(VERNALIS, Winnersh, United Kingdom) |
|
| | Identification of Leads from the Tres Cantos Antimalarial Set: Cyclopropyl Carboxamides Show Good Oral Bioavailability and Efficacy In Malarial Animal Models |
Mrs Maria Lourdes RUEDA-BENEDE
(GLAXOSMITHKLINE, Tres Cantos, Spain) |
|
| | Highly Efficient Catalytic System for C-H Activation: A Novel and Practical Synthesis of Angiotensin II Receptor Blockers |
Dr Masahiko SEKI
(MITSUBISHI TANABE PHARMA CORPORATION, Fukuoka, Japan) |
|
| | The Grandisine Alkaloids as Selective δ-Opioid Receptor Agonists; When is a Natural Product not a Natural Product? |
|
|
| | Exploring the Rigid Mono- and Diamine Chemical Space |
Dr Dmytro VOLOCHNYUK
(ENAMINE LTD., Kiev, Ukraine) |
|
| | Lead identification of a new class of P2Y12 inhibitors "From a low active and insoluble HTS hit to soluble and active lead compounds" |
Mr Fredrik ZETTERBERG
(ASTRAZENECA, Gothenburg, Sweden) |
|
| | The Chemistry of Targeting Protein-Protein Interactions: Thinking Outdside of the Box |
Dr Giovanna ZINZALLA
(LONDON SCHOOL OF PHARMACY, London, United Kingdom) |
|
| <Previous page |
.jpg){kind=small}
